Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
SGMT Stock Forecast 2025-2026
$3.26
Current Price
$104.96M
Market Cap
Buy 8
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to SGMT Price Targets
+1,955.2%
To High Target of $67.00
+835.6%
To Median Target of $30.50
+53.4%
To Low Target of $5.00
SGMT Price Momentum
-9.2%
1 Week Change
+41.1%
1 Month Change
-26.6%
1 Year Change
-27.6%
Year-to-Date Change
-55.8%
From 52W High of $7.38
+88.4%
From 52W Low of $1.73
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Sagimet (SGMT) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on SGMT and similar high-potential opportunities.
Latest SGMT Stock Price Targets & Analyst Predictions
Based on our analysis of 9 Wall Street analysts, SGMT has a bullish consensus with a median price target of $30.50 (ranging from $5.00 to $67.00). The overall analyst rating is Strong Buy (8.9/10). Currently trading at $3.26, the median forecast implies a 835.6% upside. This outlook is supported by 8 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Yasmeen Rahimi at Piper Sandler, projecting a 1,955.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SGMT Analyst Ratings
8
Buy
1
Hold
0
Sell
SGMT Price Target Range
Low
$5.00
Average
$30.50
High
$67.00
Current: $3.26
Latest SGMT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SGMT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 13, 2025 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $32.00 |
| Mar 11, 2025 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $32.00 |
| Jan 27, 2025 | Jones Trading | Debanjana Chatterjee | Buy | Initiates | $42.00 |
| Dec 6, 2024 | Oppenheimer | Jay Olson | Outperform | Initiates | $30.00 |
| Nov 15, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $32.00 |
| Nov 12, 2024 | UBS | Eliana Merle | Buy | Initiates | $12.00 |
| Oct 31, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $32.00 |
| Oct 2, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $32.00 |
| Aug 15, 2024 | JMP Securities | Jonathan Wolleben | Market Outperform | Maintains | $32.00 |
| Aug 15, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $32.00 |
| Jul 1, 2024 | Goldman Sachs | Andrea Tan | Neutral | Maintains | $6.00 |
| Jun 14, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $32.00 |
| Jun 7, 2024 | JMP Securities | Jonathan Wolleben | Market Outperform | Reiterates | $48.00 |
| Jun 7, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $32.00 |
| May 24, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $32.00 |
| May 24, 2024 | JMP Securities | Jonathan Wolleben | Market Outperform | Reiterates | $48.00 |
| May 16, 2024 | Goldman Sachs | Andrea Tan | Buy | Maintains | $23.00 |
| May 16, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $32.00 |
| May 2, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Initiates | $32.00 |
| Mar 26, 2024 | Goldman Sachs | Andrea Tan | Buy | Maintains | $27.00 |
Sagimet Biosciences Inc. (SGMT) Competitors
The following stocks are similar to Sagimet based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Sagimet Biosciences Inc. (SGMT) Financial Data
Sagimet Biosciences Inc. has a market capitalization of $104.96M with a P/E ratio of -2.2x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -36.9%.
Valuation Metrics
Market Cap
$104.96M
Enterprise Value
$-48,146,896
P/E Ratio
-2.2x
PEG Ratio
-0.9x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+144.1%
Current Ratio
34.3x
Debt/Equity
0.1x
ROE
-36.9%
ROA
-26.5%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Sagimet Biosciences Inc. (SGMT) Business Model
About Sagimet Biosciences Inc.
What They Do
Develops therapeutics for fibrotic diseases and cancer.
Business Model
Sagimet Biosciences Inc. operates by utilizing its proprietary platform to discover and develop small molecule drugs that target critical metabolic pathways. The company generates revenue through the advancement of its drug pipeline, focusing on unmet medical needs in conditions like nonalcoholic steatohepatitis (NASH) and specific cancers, eventually aiming for partnerships, licensing agreements, or sales of its therapeutic products.
Additional Information
With a strong emphasis on precision medicine and first-in-class therapeutics, Sagimet is positioned as a key player in novel drug discovery within the pharmaceutical industry. The company's innovative approach to modulating biological receptors aims to enhance patient outcomes in complex diseases, making it a noteworthy investment opportunity in the biotechnology sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
14
CEO
Mr. David A. Happel
Country
United States
IPO Year
2023
Website
www.sagimet.comSagimet Biosciences Inc. (SGMT) Latest News & Analysis
Latest News
Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates
3 days ago
Quick Summary
A Phase 1 clinical trial for the combination of denifanstat and resmetirom is set to start in 2H 2025, with data expected in 1H 2026.
Why It Matters
The timeline for the Phase 1 trial and data readout impacts potential market entry and revenue projections for the drug combination, influencing stock valuations and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates
1 month ago
Quick Summary
Sagimet Biosciences (Nasdaq: SGMT) initiated the Denifanstat Phase 3 MASH program and received FDA Breakthrough Therapy designation for TVB-3567, targeting acne treatment.
Why It Matters
Denifanstat's Phase 3 MASH program and Breakthrough Therapy designation signify potential for accelerated drug development, impacting Sagimet's valuation and market position in acne treatments.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne
2 months ago
Quick Summary
Sagimet Biosciences has cleared its IND application for TVB-3567, its second FASN inhibitor, with a Phase 1 trial planned to start in 2025.
Why It Matters
The clearance of the IND application for TVB-3567 marks a significant milestone for Sagimet, potentially leading to new treatment options and impacting its stock value positively as clinical trials progress.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
SGMT's FASN inhibitor, Denifanstat, for MASH has received FDA Breakthrough Therapy designation after strong Phase 2b results. The company also has a diversified pipeline addressing acne, solid tumors, and GBM.
Why It Matters
SGMT's Denifanstat shows promise with FDA Breakthrough Therapy status and strong trial results, while a diversified pipeline increases growth potential, enhancing overall investment appeal.
Source: Seeking Alpha
Market Sentiment:
Positive
Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne
5 months ago
Quick Summary
Ascletis Pharma has completed enrollment of 480 patients for a Phase III trial of ASC40 (denifanstat) for moderate to severe acne, with topline results expected in Q2 2025.
Why It Matters
The completion of patient enrollment for a Phase III trial indicates progress in drug development, potentially impacting Ascletis Pharma's future revenue and market position in acne treatment.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Sagimet Biosciences has initiated phase 3 studies for denifanstat targeting MASH/MAFLD and MASH, expected before end of 2024. Acne treatment market projected to reach $17.48 billion by 2032. Phase 3 results for Acne Vulgaris anticipated by Q2 2025.
Why It Matters
Sagimet's phase 3 study initiations signal potential breakthroughs in treating MASH/MAFLD and acne, which could drive stock value and market interest ahead of 2024-2025 results.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About SGMT Stock
What is Sagimet Biosciences Inc.'s (SGMT) stock forecast for 2025?
Based on our analysis of 9 Wall Street analysts, Sagimet Biosciences Inc. (SGMT) has a median price target of $30.50. The highest price target is $67.00 and the lowest is $5.00.
Is SGMT stock a good investment in 2025?
According to current analyst ratings, SGMT has 8 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.26. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SGMT stock?
Wall Street analysts predict SGMT stock could reach $30.50 in the next 12 months. This represents a 835.6% increase from the current price of $3.26. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Sagimet Biosciences Inc.'s business model?
Sagimet Biosciences Inc. operates by utilizing its proprietary platform to discover and develop small molecule drugs that target critical metabolic pathways. The company generates revenue through the advancement of its drug pipeline, focusing on unmet medical needs in conditions like nonalcoholic steatohepatitis (NASH) and specific cancers, eventually aiming for partnerships, licensing agreements, or sales of its therapeutic products.
What is the highest forecasted price for SGMT Sagimet Biosciences Inc.?
The highest price target for SGMT is $67.00 from Yasmeen Rahimi at Piper Sandler, which represents a 1,955.2% increase from the current price of $3.26.
What is the lowest forecasted price for SGMT Sagimet Biosciences Inc.?
The lowest price target for SGMT is $5.00 from at , which represents a 53.4% increase from the current price of $3.26.
What is the overall SGMT consensus from analysts for Sagimet Biosciences Inc.?
The overall analyst consensus for SGMT is bullish. Out of 9 Wall Street analysts, 8 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $30.50.
How accurate are SGMT stock price projections?
Stock price projections, including those for Sagimet Biosciences Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 12, 2025 5:04 AM UTC